ADA Scientific Sessions 2025 Abstract

Semaglutide and Lisinopril Exerts Therapeutic Benefits in a Genetically Engineered Diabetic Nephropathy Mouse Model

By Zhong Chen, Yumeng Hou, Yuwei Zheng, M. J. Xu

Experiments in animalsInterventions

The paper

Zhong Chen, Yumeng Hou, Yuwei Zheng, M. J. Xu

Nanjing

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, late-breaking 1855-LB

doi.org/10.2337/db25-1855-lb

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Nature Medicine4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Research Square8 Oct 2026
Semaglutide improved heart artery function in pigs
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes